Study [Ref. no.] | Country | Design of included studies | No. of patients | Study population | Follow-up durations, means (Y) | AOM choice | Within Time to AOM | Mortality risk (95% CI) |
---|---|---|---|---|---|---|---|---|
Cree et al. (2003) [16] | Canada | Prospective, Observational | 81 (treated) 275 (non-treated) | F and M Age ≥ 65 | 4Y | HRT, BO, calcitonin, vit-D3 | Post-fx 6 M (37%) | 0.25 (0.06–1.12) 1-year. 0.34 (0.17–0.70) long-term. |
Lyles et al. (2007) [17] | International, multicenter | RCT | 1065 (treated) 1062 (placebo) | F and M Age ≥ 50 | 1.9 Y | Zoledronic acid | Post-op 90D | 0.72 (0.56–0.93) |
Cecilia et al. (2009) [18] | Spain | RCT | 119 (treated) 120 (placebo) | F and M Age ≥ 60 | 1Y | Alendronate | Post-op 2-4D | 0.86 (.29–1.89) |
Nurmi et al. (2009) [19] | Finland | Prospective, Observational | 103 (treated) 118 (non-treated) | F and M Age ≥ 70 (80.5%) | 4Y | HRT, BO, vit-D3, calcitonin, SERM, teriparatide | NA | 0.8–0.98 |
Cameron et al. (2010) [20] | Australia | Nested case-control | 83 (treated) 366 (non-treated) | F and M Age ≥ 65 | 5 Y | BO, HRT, vit-D3, calcitonin | NA | 0.20 (0.07–0.55) BO use in the first 3 years Non-BO use: unremarkable |
Beaupre et al. (2011) [21] | Canada | Prospective, Observational | 101 (treated) 108 (non-treated) | F and M Age ≥ 50 | 3Y | Alendronate (68%), Risedronate (21%), Etidronate (11%). | Post-fx 1Y (97%), Post-fx 1-2Y (2%), Post-fx 3Y (1%) | 0.37 (0.28–0.51) per Year 0.92 (0.88–0.97) per Month |
Osaki et al. (2012) [22] | Japan | Prospective Observational | 184 (treated) 445 (non-treated) | F Age ≥ 70 (93.6%) | 3Y | Risedronate | At the time of discharge from hospital | 0.29 (0.04–2.37) |
Bondo et al. (2013) [23] | Danish | Retrospective, Observational | 1086 (treated) 2147 (non-treated) | F and M Age ≥ 55 | 3.8Y | BO | Post-fx 4 M | 0.76 (0.68–0.85) |
Brozek et al. (2016) [24] | Austrian | Retrospective, Observational | 2166 (treated) 4332 (non-treated) | F and M Age ≥ 50 | 4Y | BO | Post-fx 1Y | 0.24 (0.15–0.40) 90-days 0.43 (0.36–0.52) 1-year 0.48 (0.42–0.55) 3-year |
Cengiz et al. (2016) [25] | Turkey | RCT | 56 (treated) 58 (placebo) | F and M Age ≥ 65 | 1Y | Zolendronic acid | Post-op 2 W | 0.41 (0.20–0.86) |
Current study (2019) | Taiwan | Retrospective, Observational | 2092 (treated) 2092 (non-treated) | F and M Age ≥ 65 | 5Y | BO, raloxifene, calcitonin, teriparatide | Post-fx 6 M | 0.63 (0.58–0.68) Treated 0.42 (0.31–0.52) Adherence 0.84 (0.75–0.93) Non-adherence |